Thematic Exposure -- 9.2/10
McKesson is the #1 player (~41% share) in a textbook oligopoly controlling >90% of US pharmaceutical
distribution. Multi-secular growth vectors include GLP-1 distribution ($14B/quarter, +26% YoY),
a rapidly scaling oncology platform (37% segment growth), biopharma services with AI-driven
efficiency gains, and a planned Med-Surg IPO catalyst in H2 CY2027. TAM of $600B+ in US pharma
distribution is growing mid-to-high single digits annually.
Weight: 25%
Oligopoly Assessment: US Drug Distribution
| Company | Ticker | Approx. Market Share |
|---|---|---|
| McKesson | MCK | ~41% |
| Cencora (fka AmerisourceBergen) | COR | ~35% |
| Cardinal Health | CAH | ~22% |
| Combined | >90% |
Source: IntuitionLabs - US Drug Wholesalers: Big 3 Market Control.
Barriers to entry are immense (regulatory, scale, relationships, capital). No new entrant has emerged in decades.
Segment Revenue Breakdown (CY25Q4 / FY26Q3)
| Segment | Revenue ($M) | % of Total | YoY Growth | Daloopa |
|---|---|---|---|---|
| North American Pharmaceutical | $88,322 | 83.2% | 9% | FY26Q3 |
| Oncology & Multispecialty | $13,010 | 12.3% | 37% | FY26Q3 |
| Prescription Technology Solutions | $1,500 | 1.4% | 9% | FY26Q3 |
| Medical-Surgical Solutions | $2,991 | 2.8% | 1% | FY26Q3 |
| Other/Corp | ~$335 | 0.3% | -- | -- |
1. GLP-1 Distribution Tailwind
$14B/Quarter Revenue -- +26% YoY -- Primary Backbone for Novo Nordisk and Eli Lilly
GLP-1 revenue hit $14B in Q3 FY2026, up 26% year-over-year. McKesson is the primary distribution
backbone for Novo Nordisk and Eli Lilly GLP-1 products. This is a secular tailwind with years
of runway as obesity and diabetes treatments expand indications, supply normalizes, and global
adoption increases. MCK is investing in cold chain expansion with a 50% increase in refrigeration
capacity to deepen its competitive moat.
GLP-1 Quarterly Revenue
$14B
Q3 FY2026
GLP-1 YoY Growth
+26%
Secular tailwind
Cold Chain Expansion
+50%
Refrigeration capacity increase
2. Oncology Platform
37% Segment Growth -- 3,400 Providers -- FL Cancer Specialists + Prism Vision Acquisitions
The Oncology and Multispecialty segment is the fastest-growing at 37% YoY (24% organic). The US
Oncology Network encompasses approximately 3,400 providers. Recent acquisitions -- Florida Cancer
Specialists and Prism Vision/Core Ventures -- are expanding the platform into ophthalmology and
retina care. FY2026 segment operating profit is guided to grow 51-55%, creating a vertically
integrated oncology ecosystem.
Segment Revenue Growth
37% YoY
24% organic
US Oncology Providers
~3,400
Network scale
Segment OP Growth Guide
51-55%
FY2026 guidance
Key Acquisitions
FL Cancer
+ Prism Vision / Core Ventures
3. Biopharma Services / Prescription Technology
50 New Programs Across 43 Brands -- AI/Automation Driving Margin Expansion
Prior authorization, patient access, and affordability solutions added 50 new programs across 43
unique brands. Revenue is growing 9% with operating profit growing 18%, demonstrating meaningful
margin expansion via AI and automation. Concrete efficiency gains include 120 more patients per FTE
in verification season, 75% DSCSA inquiry deflection, and 138 basis points of operating leverage
improvement.
New Programs Added
50
Across 43 unique brands
Revenue Growth
9%
OP growing 18% (margin expansion)
AI Efficiency Gain
+120
More patients per FTE
OpEx Leverage
138bp
Improvement in opex/GP ratio
4. Medical-Surgical Separation (IPO Catalyst)
IPO Targeted H2 CY2027 -- TSAs in Place as of Jan 1, 2026
McKesson announced plans for an IPO of its Medical-Surgical Solutions segment, targeted for the
second half of CY2027. Transitional service agreements (TSAs) have been in place since January 1,
2026. This is a value-unlock catalyst that simplifies the corporate story and creates potential for
a sum-of-the-parts re-rating. The segment generates approximately $3B in quarterly revenue with
low single-digit growth.
IPO Target
H2 CY2027
Value-unlock catalyst
Segment Revenue
~$3B/Q
Medical-Surgical Solutions
TSA Status
In Place
Effective Jan 1, 2026
TAM Assessment
US Pharma Distribution TAM
$600B+
Growing mid-to-high single digits
MCK Market Share
~41%
#1 position in oligopoly
TAM Growth Drivers
Multi-Vector
Drug pricing, new launches, GLP-1, biosimilars
US pharmaceutical distribution TAM exceeds $600B and is growing mid-to-high single digits annually,
driven by drug price inflation, new specialty launches, biosimilar adoption, and GLP-1 expansion.
The oncology and multispecialty TAM is expanding rapidly with new therapies and community-based
care models.
Score Rationale
9.2/10 — Textbook oligopoly leader with
41% share in a market where the Big 3 control >90%. Multi-secular growth vectors span GLP-1
distribution ($14B/quarter, +26% YoY), a rapidly scaling oncology platform (37% growth, 3,400
providers), biopharma services with AI-driven margin expansion, and a Med-Surg IPO catalyst.
The $600B+ TAM is growing mid-to-high single digits with barriers to entry that have prevented
new entrants for decades. One of the strongest thematic setups in all of healthcare. The score
does not reach 9.5+ because: (1) the core distribution business is inherently low-margin
(~3.5% gross margin), limiting upside per incremental revenue dollar, and (2) the Med-Surg IPO
timing is subject to market conditions.
Data sourced from Daloopa and company filings (FY2026Q3, FY2026Q2, FY2026Q1 transcripts).